| |
Schwaab T, Schwarzer A, Wolf B, Crocenzi TS, Seigne JD, Crosby NA, Cole BF, Fisher JL, Uhlenhake JC, Mellinger D, Foster C, Szczepiorkowski ZM, Webber SM, Schned AR, Harris RD, Barth RJ Jr, Heaney JA, Noelle RJ, Ernstoff MS
Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.
Clin Cancer Res 2009 Aug 1; 15(15):4986-92
PMID: 19622576 [PubMed - in process]
Newsome BW, Ernstoff MS
The clinical pharmacology of therapeutic monoclonal antibodies in the treatment of malignancy; have the magic bullets arrived?
Br J Clin Pharmacol 2008 Jul; 66(1):6-19
PMID: 18503606 [PubMed - indexed for MEDLINE]
Ahonen CL, Wasiuk A, Fuse S, Turk MJ, Ernstoff MS, Suriawinata AA, Gorham JD, Kedl RM, Usherwood EJ, Noelle RJ
Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines.
Blood 2008 Mar 15; 111(6):3116-25
PMID: 18202224 [PubMed - indexed for MEDLINE]
Schwaab T, Fisher JL, Meehan KR, Fadul CE, Givan AL, Ernstoff MS
Dye dilution proliferation assay: application of the DDPA to identify tumor-specific T cell precursor frequencies in clinical trials.
Immunol Invest 2007; 36(5-6):649-64
PMID: 18161523 [PubMed - indexed for MEDLINE]
Ernstoff MS, Crocenzi TS, Seigne JD, Crosby NA, Cole BF, Fisher JL, Uhlenhake JC, Mellinger D, Foster C, Farnham CJ, Mackay K, Szczepiorkowski ZM, Webber SM, Schned AR, Harris RD, Barth RJ Jr, Heaney JA, Noelle RJ
Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang.
Clin Cancer Res 2007 Jan 15; 13(2 Pt 2):733s-740s
PMID: 17255302 [PubMed - indexed for MEDLINE]
Titus-Ernstoff L, Ding J, Perry AE, Spencer SK, Cole BF, Ernstoff MS
Factors associated with atypical moles in New Hampshire, USA.
Acta Derm Venereol 2007; 87(1):43-8
PMID: 17225015 [PubMed - indexed for MEDLINE]
Perez RP, Lewis LD, Beelen AP, Olszanski AJ, Johnston N, Rhodes CH, Beaulieu B, Ernstoff MS, Eastman A
Modulation of cell cycle progression in human tumors: a pharmacokinetic and tumor molecular pharmacodynamic study of cisplatin plus the Chk1 inhibitor UCN-01 (NSC 638850).
Clin Cancer Res 2006 Dec 1; 12(23):7079-85
PMID: 17145831 [PubMed - indexed for MEDLINE]
Titus-Ernstoff L, Perry AE, Spencer SK, Gibson J, Ding J, Cole B, Ernstoff MS
Multiple primary melanoma: two-year results from a population-based study.
Arch Dermatol 2006 Apr; 142(4):433-8
PMID: 16618861 [PubMed - indexed for MEDLINE]
Schwaab T, Tretter CP, Gibson JJ, Cole BF, Schned AR, Harris R, Fisher JL, Crosby N, Stempkowski LM, Heaney JA, Ernstoff MS
Tumor-related immunity in prostate cancer patients treated with human recombinant granulocyte monocyte-colony stimulating factor (GM-CSF).
Prostate 2006 May 1; 66(6):667-74
PMID: 16425182 [PubMed - indexed for MEDLINE]
Crocenzi TS, Tretter CP, Schwaab T, Schned AR, Heaney JA, Cole BF, Fisher JL, Ernstoff MS
Impaired cytolytic activity in peripheral blood T cells from renal cell carcinoma patients.
Clin Immunol 2005 Oct; 117(1):6-11
PMID: 16027041 [PubMed - indexed for MEDLINE]
|
